Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 12/20 | 0.37 |
| ▸ | CTSS | P25774 | 6/20 | 0.37 |
| ▸ | CTSL | P07711 | 1/20 | 0.36 |
| ▸ | CTSB | P07858 | 1/20 | 0.36 |
| ▸ | PPARG | P37231 | 4/20 | 0.34 |
| ▸ | PPARA | Q07869 | 4/20 | 0.34 |
| ▸ | PPARD | Q03181 | 2/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9940063 | 0.81 | CTSK (0.38) | CTSKCTSSCTSLCTSBCYP2D6 | |
| SCHEMBL9929780 | 0.75 | CTSK (0.39) | CTSKCTSSCTSLCTSBPPARG | |
| SCHEMBL14984731 | 0.74 | CTSK (0.49) | CTSKCTSSCTSLCTSBPPARG | |
| SCHEMBL168105 | 0.74 | CTSK (0.49) | CTSKCTSSCTSLCTSBPPARG | |
| SCHEMBL1486220 | 0.72 | CTSS (0.50) | CTSKCTSSCTSLCTSBPPARG | |
| SCHEMBL3323682 | 0.72 | CTSS (0.50) | CTSKCTSSCTSLCTSBPPARG | |
| SCHEMBL688341 | 0.72 | CTSS (0.50) | CTSKCTSSCTSLCTSBPPARG | |
| SCHEMBL30385524 | 0.71 | CYP1A2 (0.47) | CTSKCTSSCTSLCTSBCYP2D6 | |
| SCHEMBL17921680 | 0.71 | CTSK (0.47) | CTSKCTSSCTSLCTSBPPARG | |
| SCHEMBL1235160 | 0.71 | CTSK (0.49) | CTSKCTSSCTSLCTSBPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9045524-B2 | Selective caspase inhibitors and uses thereof | NOVAGENESIS FOUNDATION (CH) | 2015-06-02 | — | — | US | disclosed |
| US-20120157394-A1 | SELECTIVE CASPASE INHIBITORS AND USES THEREOF | NEW WORLD LABORATORIES, INC. (CA) | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157394-A1 | SELECTIVE CASPASE INHIBITORS AND USES THEREOF | CASP1, VIP, CASP5 | CTSK 90/4885CTSS 73/4885CTSL 30/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.